View ValuationSynbio Tech 将来の成長Future 基準チェック /06現在、 Synbio Techの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長35.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 15First quarter 2026 earnings released: EPS: NT$0.39 (vs NT$1.26 in 1Q 2025)First quarter 2026 results: EPS: NT$0.39 (down from NT$1.26 in 1Q 2025). Revenue: NT$214.5m (down 8.2% from 1Q 2025). Net income: NT$13.3m (down 66% from 1Q 2025). Profit margin: 6.2% (down from 17% in 1Q 2025). The decrease in margin was primarily driven by lower revenue.Buy Or Sell Opportunity • Apr 23Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 32% to NT$58.50. The fair value is estimated to be NT$74.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 23%.Buy Or Sell Opportunity • Apr 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 28% to NT$59.80. The fair value is estimated to be NT$74.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 23%.Reported Earnings • Mar 15Full year 2025 earnings released: EPS: NT$5.29 (vs NT$5.43 in FY 2024)Full year 2025 results: EPS: NT$5.29. Revenue: NT$1.04b (up 5.0% from FY 2024). Net income: NT$176.0m (up 3.4% from FY 2024). Profit margin: 17% (in line with FY 2024).Declared Dividend • Mar 14Dividend reduced to NT$3.00Dividend of NT$3.00 is 14% lower than last year. Ex-date: 27th March 2026 Payment date: 28th April 2026 Dividend yield will be 4.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 54% per year over the past 2 years and payments have been stable during that time. Earnings per share has grown by 8.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Mar 13Synbio Tech Inc. announces Annual dividend, payable on April 28, 2026Synbio Tech Inc. announced Annual dividend of TWD 3.0000 per share payable on April 28, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.お知らせ • Mar 12Synbio Tech Inc., Annual General Meeting, May 29, 2026Synbio Tech Inc., Annual General Meeting, May 29, 2026, at 09:00 Taipei Standard Time. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city TaiwanBuy Or Sell Opportunity • Mar 11Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to NT$69.60. The fair value is estimated to be NT$87.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 26%.Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Director Zhao-Ming Liu was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Nov 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.12b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (14% operating cash flow to total debt). High level of non-cash earnings (29% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (NT$3.12b market cap, or US$99.2m).New Risk • Nov 12New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (30% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.2% average weekly change).Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: NT$0.92 (vs NT$1.81 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.92 (down from NT$1.81 in 3Q 2024). Revenue: NT$211.3m (down 23% from 3Q 2024). Net income: NT$31.8m (down 44% from 3Q 2024). Profit margin: 15% (down from 21% in 3Q 2024). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Aug 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$131, the stock trades at a trailing P/E ratio of 24.9x. Average forward P/E is 22x in the Biotechs industry in Taiwan. Total returns to shareholders of 64% over the past year.Reported Earnings • Aug 12Second quarter 2025 earnings released: EPS: NT$1.92 (vs NT$1.74 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.92 (up from NT$1.74 in 2Q 2024). Revenue: NT$309.1m (up 28% from 2Q 2024). Net income: NT$62.6m (up 15% from 2Q 2024). Profit margin: 20% (down from 23% in 2Q 2024). The decrease in margin was driven by higher expenses.New Risk • Jul 22New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (22% accrual ratio). Minor Risk High level of debt (42% net debt to equity).New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (NT$2.57b market cap, or US$86.0m).お知らせ • May 08Synbio Tech Inc. has filed a Follow-on Equity Offering.Synbio Tech Inc. has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 2,122,000 Price(minimum): TWD 46.31 Security Name: Shares Security Type: Common Stock Securities Offered: 560,000 Price\Range: TWD 56.5 Transaction Features: Subsequent Direct ListingNew Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (NT$1.93b market cap, or US$58.3m).お知らせ • Mar 13+ 1 more updateSynbio Tech Inc. announces Annual dividend, payable on April 22, 2025Synbio Tech Inc. announced Annual dividend of TWD 3.5000 per share payable on April 22, 2025, ex-date on March 27, 2025 and record date on March 30, 2025.New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (NT$2.62b market cap, or US$80.9m).お知らせ • Apr 05Synbio Tech Inc., Annual General Meeting, Jun 27, 2024Synbio Tech Inc., Annual General Meeting, Jun 27, 2024.お知らせ • Apr 04SYNPET, Subsidiary Brand of SYNBIO TECH Announces to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024SYNPET, a subsidiary brand of SYNBIO TECH announced its participation at the upcoming Petfood Forum 2024. This premier event for pet food and pet treat manufacturers and industry suppliers will take place from April 29, 2024 to May 1, 2024 at the Kansas City Convention Center in Kansas City, Missouri, USA. At Petfood Forum 2024, SYNPET will showcase its headlining product: GABA 20: A postbiotic designed for pets to boost immunity, reduce stress and aggressive behavior. Produced through lactic acid bacteria fermentation, SYNPET's GABA has high bioavailability and boasts a purity over 20%, offering stability for easy processing into various formats such as capsules, powder, and pet food formulations. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Synbio Tech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:1295 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261,019150-524144N/A12/31/20251,039176-562143N/A9/30/20251,001156-363167N/A6/30/20251,063180-270225N/A3/31/2025995172-217212N/A12/31/2024989170-49262N/A9/30/2024975180-114264N/A6/30/2024904143-75233N/A3/31/2024857119-1249N/A12/31/2023823113-114214N/A9/30/202377299-110192N/A6/30/202375196-71202N/A3/31/202374594-52195N/A12/31/202273993-33187N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1295の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 1295の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 1295の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 1295の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 1295の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1295の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 10:09終値2026/05/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Synbio Tech Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Hsiu Chi LinMasterlink Securities Investment Advisory
Reported Earnings • May 15First quarter 2026 earnings released: EPS: NT$0.39 (vs NT$1.26 in 1Q 2025)First quarter 2026 results: EPS: NT$0.39 (down from NT$1.26 in 1Q 2025). Revenue: NT$214.5m (down 8.2% from 1Q 2025). Net income: NT$13.3m (down 66% from 1Q 2025). Profit margin: 6.2% (down from 17% in 1Q 2025). The decrease in margin was primarily driven by lower revenue.
Buy Or Sell Opportunity • Apr 23Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 32% to NT$58.50. The fair value is estimated to be NT$74.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 23%.
Buy Or Sell Opportunity • Apr 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 28% to NT$59.80. The fair value is estimated to be NT$74.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 23%.
Reported Earnings • Mar 15Full year 2025 earnings released: EPS: NT$5.29 (vs NT$5.43 in FY 2024)Full year 2025 results: EPS: NT$5.29. Revenue: NT$1.04b (up 5.0% from FY 2024). Net income: NT$176.0m (up 3.4% from FY 2024). Profit margin: 17% (in line with FY 2024).
Declared Dividend • Mar 14Dividend reduced to NT$3.00Dividend of NT$3.00 is 14% lower than last year. Ex-date: 27th March 2026 Payment date: 28th April 2026 Dividend yield will be 4.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 54% per year over the past 2 years and payments have been stable during that time. Earnings per share has grown by 8.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Mar 13Synbio Tech Inc. announces Annual dividend, payable on April 28, 2026Synbio Tech Inc. announced Annual dividend of TWD 3.0000 per share payable on April 28, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
お知らせ • Mar 12Synbio Tech Inc., Annual General Meeting, May 29, 2026Synbio Tech Inc., Annual General Meeting, May 29, 2026, at 09:00 Taipei Standard Time. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city Taiwan
Buy Or Sell Opportunity • Mar 11Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to NT$69.60. The fair value is estimated to be NT$87.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 26%.
Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Director Zhao-Ming Liu was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Nov 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.12b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (14% operating cash flow to total debt). High level of non-cash earnings (29% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (NT$3.12b market cap, or US$99.2m).
New Risk • Nov 12New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (30% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.2% average weekly change).
Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: NT$0.92 (vs NT$1.81 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.92 (down from NT$1.81 in 3Q 2024). Revenue: NT$211.3m (down 23% from 3Q 2024). Net income: NT$31.8m (down 44% from 3Q 2024). Profit margin: 15% (down from 21% in 3Q 2024). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Aug 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$131, the stock trades at a trailing P/E ratio of 24.9x. Average forward P/E is 22x in the Biotechs industry in Taiwan. Total returns to shareholders of 64% over the past year.
Reported Earnings • Aug 12Second quarter 2025 earnings released: EPS: NT$1.92 (vs NT$1.74 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.92 (up from NT$1.74 in 2Q 2024). Revenue: NT$309.1m (up 28% from 2Q 2024). Net income: NT$62.6m (up 15% from 2Q 2024). Profit margin: 20% (down from 23% in 2Q 2024). The decrease in margin was driven by higher expenses.
New Risk • Jul 22New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (22% accrual ratio). Minor Risk High level of debt (42% net debt to equity).
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (NT$2.57b market cap, or US$86.0m).
お知らせ • May 08Synbio Tech Inc. has filed a Follow-on Equity Offering.Synbio Tech Inc. has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 2,122,000 Price(minimum): TWD 46.31 Security Name: Shares Security Type: Common Stock Securities Offered: 560,000 Price\Range: TWD 56.5 Transaction Features: Subsequent Direct Listing
New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (NT$1.93b market cap, or US$58.3m).
お知らせ • Mar 13+ 1 more updateSynbio Tech Inc. announces Annual dividend, payable on April 22, 2025Synbio Tech Inc. announced Annual dividend of TWD 3.5000 per share payable on April 22, 2025, ex-date on March 27, 2025 and record date on March 30, 2025.
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (NT$2.62b market cap, or US$80.9m).
お知らせ • Apr 05Synbio Tech Inc., Annual General Meeting, Jun 27, 2024Synbio Tech Inc., Annual General Meeting, Jun 27, 2024.
お知らせ • Apr 04SYNPET, Subsidiary Brand of SYNBIO TECH Announces to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024SYNPET, a subsidiary brand of SYNBIO TECH announced its participation at the upcoming Petfood Forum 2024. This premier event for pet food and pet treat manufacturers and industry suppliers will take place from April 29, 2024 to May 1, 2024 at the Kansas City Convention Center in Kansas City, Missouri, USA. At Petfood Forum 2024, SYNPET will showcase its headlining product: GABA 20: A postbiotic designed for pets to boost immunity, reduce stress and aggressive behavior. Produced through lactic acid bacteria fermentation, SYNPET's GABA has high bioavailability and boasts a purity over 20%, offering stability for easy processing into various formats such as capsules, powder, and pet food formulations.